PDL BioPharma, Inc. (PDLI)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

59 DAMONTE RANCH PARKWAY RENO, NV 89521

PDL BioPharma Inc. is a biopharmaceutical company focused on the discovery and development of novel antibodies in oncology and immunologic diseases. It receives royalties and other revenues through licensing agreements with various biotechnology and pharmaceutical companies based on its antibody humanization technology platform. These licensing agreements have contributed to the development by the Company's licensees of nine marketed products. The Company has several investigational compounds in clinical development for severe or life-threatening diseases, two of which it is developing in collaboration with Biogen Idec MA, Inc. (Biogen Idec). Its products include Daclizumab, Volociximab, HuLuc63, PDL192 and Nuvion. In March 2008, the Company closed the sale of the Cardiovascular Assets, which included Cardene, to EKR Therapeutics, Inc (EKR). However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR.

Data as of 2019-12-02 14:51:23 -0500
Market Cap353.974 Million Shares Outstanding114.185 Million Avg 30-day Volume
P/E Ratio Dividend Yield EPS-0.028
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low3.89 / 2.06 Next Earnings Date Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from PDLI instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 1 -100.0% 0 (0.0%) 1 (0.06%) -100.0%
Funds Holding: 10 33 -69.7% 3 (0.18%) 12 (0.7%) -75.0%
13F shares: 14.617 Million 42.094 Million -65.28% 14.544 Million 40.709 Million -64.27%
% Ownership 36.8515 35.6391
New Positions: 5 3
Increased Positions 1 5 -80.0% 1 3 -66.67%
Closed Positions 21 103 -79.61% 9 28 -67.86%
Reduced Positions 14 4
Total Calls 0 258 -100.0%
Total Puts 0 1.086 Thousand -100.0%
PUT/CALL Ratio 4.21
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding PDLI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PDLI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SILVER POINT CAPITAL L.P.

O'SHEA ROBERT J

MULE EDWARD A

  • 10% Owner
23,970,334 2021-02-01 6

GRYSKA DAVID W

  • Director
1,387 2020-12-30 8

PARK WEST ASSET MANAGEMENT LLC

  • 10% Owner
14,397,212 2020-12-30 1

MCLAUGHLIN JOHN PETER

  • Director
200,000 2020-12-21 2

STONE CHRISTOPHER LEWIS VP, GEN. COUNSEL & SECRETARY

  • Officer
405,559 2020-12-16 2

MONNET DOMINIQUE PRESIDENT AND CEO

  • Officer
734,921 2020-12-16 1

O'FARRELL ELIZABETH G.

  • Director
0 2020-11-23 3

BAZAAR ALAN LEE

  • Director
10,438 2020-11-18 2

HERNDAY NATASHA

  • Director
75,826 2020-08-19 1

IMBROGNO EDWARD VP FINANCE, CAO AND ACTING CFO

  • Officer
232,077 2020-02-07 0

JENE JILL M. VP, BUSINESS DEVELOPMENT

  • Officer
194,805 2020-01-08 0

SANDMAN PAUL W

  • Director
0 2019-06-20 0

SELICK HAROLD E

  • Director
0 2019-06-20 0

SAKS SAMUEL R

  • Director
0 2019-06-20 0

YANAI SHLOMO

  • Director
0 2019-06-20 0

GARCIA PETER S VICE PRESIDENT, CFO

  • Officer
0 2019-03-28 0

LINDELL JODY S

  • Director
256,174 2018-06-08 0

EDICK PAUL R

  • Director
214,563 2018-06-08 0

PIETZKE STEFFEN VP, FINANCE AND CAO

  • Officer
160,177 2017-12-15 0

HART DANNY J JR. VP BUSINESS DEVELOPMENT

  • Officer
387,236 2017-03-04 0

IMMUNE RESPONSE BIOPHARMA, INC.

  • SHAREHOLDER
1 2015-05-17 0

MONTEZ DAVID CONTROLLER AND CAO

  • Officer
26,719 2015-01-28 0

TOMLINSON BRUCE CHIEF FINANCIAL OFFICER

  • Officer
16,509 2012-06-21 0

FRANK FRED

  • Director
33,296 2012-06-05 0

KRUMEL CAROLINE J VPFINANCE/PRIN.ACCTING OFFICER

  • Officer
9,384 2012-01-18 0

LARSON CHRISTINE R VICE PRESIDENT AND CFO

  • Officer
62,049 2011-05-23 0

KLEIN JOSEPH III

  • Director
16,994 2009-11-04 0

WILSON KAREN J VP OF FINANCE & PAO

  • Officer
10,494 2009-05-07 0

GUGGENHIME ANDREW SVP & CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2008-12-18 0

MCCAMISH MARK ANTHONY SVP & CMO

  • Officer
No longer subject to file 2008-12-18 0

SARENA FRANCIS WILLARD VP/GEN COUNSEL/SECY

  • Officer
5,756 2008-09-15 0

CROSS HERB CORP CONTROLLER/PRIN ACCTG OFF

  • Officer
5,031 2008-09-15 0

LYONS GARY A

  • Director
0 2008-08-13 0

HORA MANINDER VP OF PRODUCT OPERATIONS

  • Officer
4,657 2008-08-13 0

MURRAY RICHARD /CA/ EVP & CSO

  • Officer
70,159 2008-07-21 0

GOODWIN BRADFORD S CHAIRPERSON OF THE BOARD

  • Officer
  • Director
0 2008-07-16 0

KORN LAURENCE JAY

  • Director
0 2008-05-28 0

DAWES KAREN A CHAIRPERSON OF THE BOARD

  • Officer
  • Director
2,250 2008-04-29 0

GAGE L PATRICK INTERIM CEO

  • Officer
  • Director
19,555 2008-04-28 0

SHAH JAISIM SVP, MKTG & BUS. AFFAIRS

  • Officer
16,125 2008-04-28 0

SAXE JON S

  • Director
421,680 2008-04-09 0

IWANICKI DAVID VP, SALES & SALES OPERATIONS

  • Officer
0 2008-01-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund PDLI -20.0 shares, $-56.4 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund PDLI -34.0 shares, $-95.88 2020-03-31 N-PORT
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund PDLI -4500.0 shares, $-11115.0 2021-03-31 N-PORT
iShares Trust- iShares Russell 2000 Value ETF PDLI -1188.0 shares, $-2934.36 2021-03-31 N-PORT
iShares Trust- iShares Nasdaq Biotechnology ETF PDLI -4374.0 shares, $-10803.78 2021-03-31 N-PORT

Elevate your investments